The apparent protective association we observe with prostate cancer risk is in line with the results from multiple phase I/II trials of TNFRSF10B agonists that support their use for the treatment of multiple cancer endpoints, though not yet including prostate cancer.60, 61, 62. The gene discussed is TNFRSF10B; the disease is prostate cancer.